Psychiatry AtlasMedication guide · United States

Stimulant medicine

Lisdexamfetamine (Vyvanse)

Generic name
lisdexamfetamine dimesylate
Brand names
Vyvanse
Medication class
Stimulant medicine
Forms covered
Vyvanse capsules; Vyvanse chewable tablets

Article updated: 2026-10-30 · Sources last checked: 2026-11-05

Medication Safety Alerts

FDA Boxed Warning

Vyvanse capsules; Vyvanse chewable tablets.

Vyvanse has a high potential for abuse, misuse and addiction. Misuse can cause overdose and death. Assess and monitor risk before and during treatment; store securely, never share, and dispose of unused medicine safely.

Lisdexamfetamine (Vyvanse) treats ADHD from age 6 and moderate to severe binge eating disorder in adults. It is not approved for weight loss and carries risks of misuse, addiction, and overdose.

What to expect: For ADHD, benefit can be present during the day a dose is taken, but finding the right treatment plan and reviewing appetite, sleep, and heart effects takes follow-up.

Warning signs · Medicine forms
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Attention-deficit/hyperactivity disorder (ADHD) — Adults and children aged 6 years and older. Used within a broader treatment plan. Use below age 6 is not recommended because exposure and adverse effects were greater in younger children.Vyvanse capsules; Vyvanse chewable tablets.
  • Moderate to severe binge eating disorder — Adults. This approval does not cover obesity, ordinary overeating or weight loss. Pediatric binge eating disorder use is not established.Vyvanse capsules; Vyvanse chewable tablets.

Read more: ADHD.

What should I expect?

For ADHD, benefit can be present during the day a dose is taken, but finding the right treatment plan and reviewing appetite, sleep, and heart effects takes follow-up. For binge eating disorder, progress means fewer binge-eating episodes over time, not simply a reduced appetite or weight loss.

Agree on a follow-up plan when treatment starts. Contact the prescriber if symptoms worsen, side effects disrupt daily life, or there is no useful improvement by the planned review; do not change the dose yourself.

How do I take it safely?

Take in the morning with or without food; afternoon doses can disturb sleep. Chew chewable tablets thoroughly. Capsules may be swallowed whole or their entire contents mixed with yogurt, water, or orange juice and taken immediately. Do not split a capsule dose or store the mixture.

Keep it securely stored and never share it. Before and during treatment, review misuse risk, heart history, blood pressure, pulse, mood, tics, and painful or discolored fingers or toes. Children need height and weight checks; kidney impairment may change the dose limit.

Allergy to amphetamine products or product ingredients. Current MAOI use or use within 14 days after stopping an MAOI.

The label advises avoiding use in serious structural heart disease, serious rhythm disorders, or other serious heart disease.

MAO inhibitors can produce a dangerous blood-pressure reaction. Serotonergic medicines and strong CYP2D6 inhibitors can increase the risk of serotonin syndrome; signs include fever, confusion, agitation, muscle stiffness or twitching and unstable pulse. Medicines that change urine acidity can change amphetamine exposure. Do not use supplements or antacids to alter the medicine’s effects. Review all prescribed medicines, nonprescription products and supplements with the pharmacist.

Pregnancy data are insufficient to establish a precise drug-associated risk; stimulant effects and untreated illness both matter in an individual discussion. The Vyvanse label recommends against breastfeeding during treatment because amphetamine enters milk and serious infant effects are possible.

ADHD approval starts at age 6; binge eating disorder approval is for adults. Younger children can have higher drug exposure and more adverse reactions. Older adults were insufficiently represented in trials and may need particular attention to kidney, cardiovascular and medication-interaction risks.

Do not double a missed dose. Because the label discourages afternoon dosing, ask the pharmacist how to handle a late remembered dose. Discuss stopping with the prescriber; abrupt discontinuation or large reduction after prolonged stimulant use can cause depressed mood, fatigue, sleep changes and increased appetite.

What side effects should I know about?

  • Reduced appetite and weight, dry mouth, nausea or abdominal discomfort.
  • Insomnia, anxiety, irritability, jitteriness and increased heart rate.
  • Vyvanse is not approved or recommended for children younger than 6. Studies found higher drug exposure and more adverse effects, including weight loss, in this age group. Children taking it need height and weight monitoring; report poor appetite, weight loss or slowed growth to the prescriber.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Chest pain, fainting, severe shortness of breath or an irregular heartbeat need urgent assessment.
  • High fever with confusion, agitation, muscle stiffness or twitching may indicate serotonin syndrome.
  • New hallucinations or mania, severe allergic swelling, seizures or suspected overdose require urgent medical help.
  • Get emergency help for trouble breathing, collapse, a seizure, or severe or rapidly worsening symptoms. If thoughts of self-harm put you in immediate danger, seek emergency care now.

What else should I know to stay safe?

  • Store securely and never share. Do not use after an amphetamine allergy or within 14 days after an MAOI. Avoid use in serious heart disease. Monitor blood pressure, pulse, mood, tics, and circulation in fingers or toes; children also need height and weight checks.
  • Serotonin-affecting medicines, strong CYP2D6 inhibitors, and medicines that change urine acidity can alter risk or exposure. Do not use supplements or antacids to intensify the effect. Kidney impairment can change dose limits, and abrupt reductions after prolonged use can cause withdrawal; arrange changes with the prescriber.
  • Discuss pregnancy and breastfeeding. The Vyvanse label recommends against breastfeeding during treatment because amphetamine enters milk. ADHD approval begins at age 6 and binge eating disorder approval is adult only; older adults may have additional heart, kidney, and interaction risks.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • A prodrug still has stimulant risks. Conversion in the body does not make Vyvanse free of misuse, addiction, or overdose risk.
  • Reduced appetite is a side effect, not the treatment goal. For ADHD, follow attention and daily functioning; for binge eating disorder, follow binge episodes and the wider recovery plan.

How does it work?

The body converts lisdexamfetamine into dextroamphetamine, the active stimulant. This changes the handling of dopamine and norepinephrine, chemical messengers used by nerve cells. The conversion and messenger effects are established, but the complete link to symptom improvement is not known.

Explore more in Brain & Science: Stimulant Transport and Release: Amphetamine.

How was this medicine developed?

The FDA approved Vyvanse capsules in 2007. Its prodrug design means the body converts it to the active stimulant dextroamphetamine. Later approvals added chewable tablets and adult binge eating disorder treatment.

How do I say the name?

Lisdexamfetamine: lis-dex-am-FET-uh-meen. Capital letters show the stressed syllable.

Medicine forms and official information

Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Vyvanse: current product prescribing information
  2. Lisdexamfetamine: patient information
  3. Vyvanse capsules: FDA approval and product record
  4. Vyvanse: FDA prescribing information, April 2026
  5. Vyvanse: Package Insert / Prescribing Information / MOA
  6. Vyvanse chewable tablets: FDA approval and product record
  7. Concerta: prescribing information
  8. Atomoxetine: FDA prescribing information
  9. Serotonin syndrome: MedlinePlus Medical Encyclopedia
  10. Monitoring a person during and after antidepressant switching – NHS SPS - Specialist Pharmacy Service – The first stop for professional medicines advice
  11. Schizophrenia
  12. NIMH: Understanding psychosis

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top